Join the Cotempla XR-ODT group to help and get support from people like you.
Cotempla XR-ODT News
Many ADHD Medications Lead to Increases in Blood Pressure and Heart Rate
MONDAY, April 21, 2025 – Many pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD) lead to increases in hemodynamic signs, including blood pressure and pulse, according to...
ADHD Drugs Generally Safe For Heart Health, Review Says
MONDAY, April 14, 2025 – Worried about taking the ADHD meds you’ve been prescribed because they might harm your heart health? There’s no need to fret, according to a new evidence review. ADHD med...
Big Drop in U.S. Kids, Teens Misusing Prescription Meds
WEDNESDAY, July 24, 2024 – Misuse of illicit prescription drugs is falling dramatically among U.S. high school students, a new study says. The percentage of seniors who say they’ve misused p...
FDA Medwatch Alert: FDA Updating Warnings to Improve Safe Use of Prescription Stimulants Used to Treat ADHD and Other Conditions
What safety concern is FDA announcing? To address continuing concerns of misuse, abuse, addiction, and overdose of prescription stimulants, the U.S. Food and Drug Administration (FDA) is requiring...
Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
DALLAS and FORT WORTH, Texas, June 19, 2017 (GLOBE NEWSWIRE) – Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Further information
Related condition support groups
Attention-Deficit Hyperactivity Disorder (ADHD)